- Home
- XFOR vs CHEB Comparison
XFOR vs CHEB Comparison
Compare XFOR & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- CHEB
- Stock Information
- Founded
- XFOR 2014
- CHEB 2024
- Country
- XFOR United States
- CHEB Singapore
- Employees
- XFOR N/A
- CHEB N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- CHEB
- Sector
- XFOR Health Care
- CHEB
- Exchange
- XFOR Nasdaq
- CHEB NYSE
- Market Cap
- XFOR 118.4M
- CHEB 120.0M
- IPO Year
- XFOR N/A
- CHEB 2024
- Fundamental
- Price
- XFOR $0.47
- CHEB $10.18
- Analyst Decision
- XFOR Strong Buy
- CHEB
- Analyst Count
- XFOR 3
- CHEB 0
- Target Price
- XFOR $3.50
- CHEB N/A
- AVG Volume (30 Days)
- XFOR 6.8M
- CHEB 11.4K
- Earning Date
- XFOR 03-20-2025
- CHEB 01-01-0001
- Dividend Yield
- XFOR N/A
- CHEB N/A
- EPS Growth
- XFOR N/A
- CHEB N/A
- EPS
- XFOR N/A
- CHEB N/A
- Revenue
- XFOR $1,123,000.00
- CHEB N/A
- Revenue This Year
- XFOR N/A
- CHEB N/A
- Revenue Next Year
- XFOR $590.67
- CHEB N/A
- P/E Ratio
- XFOR N/A
- CHEB N/A
- Revenue Growth
- XFOR N/A
- CHEB N/A
- 52 Week Low
- XFOR $0.26
- CHEB $9.96
- 52 Week High
- XFOR $1.60
- CHEB $26.25
- Technical
- Relative Strength Index (RSI)
- XFOR 41.75
- CHEB N/A
- Support Level
- XFOR $0.46
- CHEB N/A
- Resistance Level
- XFOR $0.54
- CHEB N/A
- Average True Range (ATR)
- XFOR 0.05
- CHEB 0.00
- MACD
- XFOR -0.01
- CHEB 0.00
- Stochastic Oscillator
- XFOR 5.63
- CHEB 0.00
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.